The Longevity Fund, now operating as age1, is a venture capital firm focused on investing in early-stage biotech and life sciences companies dedicated to extending human healthy lifespan and treating aging as a disease. Their strategy centers on backing mission-oriented, founder-led companies with unconventional backgrounds that aim to bring the first longevity drugs to market.
50% of their portfolio is in Biotech & Life Sciences. Their most common stage is seed (50% of deals). Average disclosed round size is $37.9M (across 6 rounds with reported amounts).
Portfolio
6
Fund Size
$37M
Top Stage
Seed
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| CCustoMED | Seed | $6M | Oct 2025 |
 Faireez | Seed | $7.5M | Mar 2025 |
 Senda Biosciences | Series C | $123M | Aug 2022 |
 Loyal | Series A | $27M | Sep 2021 |
 Fauna Bio | Seed | $4.1M | Apr 2019 |
 Gordian Biotechnology | Series C | $60M | — |
Top Co-Investors
Khosla Ventures1 shared
First Round Capital1 shared
Box Group1 shared
Collaborative Fund1 shared
NFX1 shared
Secret Chord Ventures1 shared
RE Angels1 shared
Qatar Investment Authority1 shared
Flagship Pioneering1 shared
Alexandria Venture Investments1 shared
Mayo Clinic1 shared
State of Michigan Retirement System1 shared
True Ventures1 shared
Pacific 8 Ventures1 shared
Wix1 shared
Varana1 shared
Israeli Innovation Authority1 shared
Founders Fund1 shared
Gigafund1 shared
Fifty Years1 shared
Last updated: 8 March 2026